Valvular & structural heart diseaseSecondary analysis
Treatment effects of dapagliflozin in patients with aortic stenosis undergoing transcatheter aortic valve implantation across left ventricular ejection fraction
- Secondary analysis of the DapaTAVI randomised trial
- pragmatic
- multicentre
- open-label
- blinded endpoint adjudication
- 39 Spanish centres
Authors' conclusion
In elderly patients undergoing TAVI, dapagliflozin reduced the risk of all-cause death or worsening HF irrespective of baseline LVEF and was safe across the full LVEF spectrum.
Study context
- Population
- Elderly patients with severe AS undergoing transcatheter aortic valve implantation (TAVI), by baseline left ventricular ejection fraction (LVEF) (≤40% vs >40%)with available baseline LVEF
- Participants
- 1,223 patients
- Comparison
- Dapagliflozin vs standard of care, by baseline LVEF
- Primary endpoint
- All-cause death or worsening heart failure (HF)
- Follow-up
- 1-year follow-up
Primary result
As reported in the abstract
All-cause death or worsening HF, treatment effect by LVEF subgroup
No significant interaction between treatment effect and baseline LVEF
P for interaction = .41
Further findings
| Outcome | LVEF ≤40% | LVEF >40% | adjusted HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Primary endpoint by baseline LVEF (prognosis) · 1-year follow-up | 20.2% | 17.0% | 1.28 (0.91–1.80) | P = 0.15 | |
| 0.512Adjusted hazard ratio (log scale) |
- Primary endpoint by baseline LVEF (prognosis): LVEF ≤40%: 213 (17.4%); LVEF >40%: 1010 (82.6%)
Safety
Safety across LVEF categories
- Safety profile comparable to control across all LVEF categories
- Genitourinary infections more frequent with dapagliflozin
Original publication
Treatment effects of dapagliflozin in patients with aortic stenosis undergoing transcatheter aortic valve implantation across left ventricular ejection fraction. Eur J Heart Fail. Published 27 August 2026. doi:10.1093/ejhf/xuag242
Summarised from the published abstract; every number is checked against it